This clinical study will evaluate the feasibility of a purified CD34 peripheral blood
progenitor cell (PBPC) transplants in patients with hematological malignancies.
The primary objectives of the study are to evaluate the recipient obtaining donor derived
neutrophil engraftment and the incidence of acute graft versus host disease [GvHD] (grade
Secondary objectives include assessments of recipient having donor derived platelet
engraftment, incidence of graft failure and chronic GvHD, overall and disease free survival,
clinical safety and device performance of the CliniMACS CD34 selection device.
Before taking part in this study, donors will have an evaluation that is the standard for
any bone marrow or blood stem cell donor. These include standard blood tests, an
electrocardiogram (EKG), and a chest X-ray. Donors will also be given a general health
questionnaire that is given to all blood donors in the United States. It should take no
more than 10 minutes to complete the questionnaire.
Donors in this study will receive standard mobilization therapy with daily G-CSF every 12
hours. The Granulocyte colony-stimulating factor (G-CSF) will be given as an injection under
the skin. The mobilization phase starts on the first day that donors receive G-CSF and
continues until the final day of the stem cell collection process (leukapheresis).
Donors in this study will receive Neupogen (white blood cell growth factor) to stimulate the
immature blood cells. They will receive two injections, twice a day for four days. On the
fourth day, assuming they have enough immature white blood cells, researchers will start the
stem cell collection process (leukapheresis).
The stem cell collection will go from 1 to 4 days until enough immature cells have been
collected, but will not be done on any day the donor's platelet count falls below 75,000.
The stem cell is called a CD34(+) cell. These cells will then be processed over a
cell-processing machine to try to purify the immature fraction of cells and remove the
T-lymphocytes that are part of the fatal graft versus host disease. The T-cell is called a
Leukapheresis, with later CD34(+) cell selection, will start on the day when circulating
CD34(+) count is at a high enough level. Leukapheresis will continue until the appropriate
count is reached. If the CD3(+) count is too high, adjustments will be made.
For those donors who cannot reach the collection goal in one series of collection attempts,
researchers will wait until the donor recovers from the first stem cell collection and try
again. If the donor is unable to reach the collection goal again, another attempt will be
made with a different donor.
The blood thinner used for the procedure will be acid citrate dextrose (ACD). Heparin may
be substituted when clinically needed. No additional blood thinners or additives should be
added beyond those normally used during leukapheresis. A unique identification and labeling
system shall be used to track the leukapheresis product from collection to infusion.
Samples will be taken from each leukapheresis product pre- and post-selection for quality
This is an investigational study. No more than 90 donors will take part in this study. All
will be enrolled at M. D. Anderson.
Before taking part in this study, recipients will have standard evaluations to determine the
stage of their disease. These may include bone marrow aspirations and biopsies and if
necessary, CT scans and chest x-rays. All recipients will go through cardiopulmonary
The recipients will have an allogeneic bone marrow transplant with pre-treatment of
thiotepa, fludarabine, melphalan, and antithymocyte globulin. This will be followed by
infusion of the peripheral blood progenitor cells.
Recipients will have daily follow-up exams in the hospital. Recipients will be evaluated at
least one to five times per week after they leave until Day 100. After that, they will have
evaluations at least once every three months until about one year and then once every six
The CliniMACS device is being provided by used of an investigational device exemption for
the FDA. Without the CliniMACS device, this procedure would not be possible.
This is an investigational study. A total of 40 patients will take part in this study. All
will be enrolled at M. D. Anderson.
1. Male or female recipients must have histopathologically confirmed diagnosis of
hematological or lymphatic malignancy in one of the following categories:
2. Acute Leukemia: Recipients must have acute leukemia in second or greater remission in
relapse, or primary refractory disease. Acute leukemia (in first remission with poor
risk factors and molecular prognosis; acute myelogenous leukemia (AML) with -5, -7,
t(6:9), +8, -11q23 and Acute lymphoblastic leukemia (ALL) with Phil+ t(9:22), t(4:11)
and secondary remission inclusive).
3. Chronic myelogenous leukemia: Chronic Myeloid Leukemia (CML) in accelerated phase,
blast crisis or second chronic phase.
4. Myelodysplastic syndrome (in high and intermediate risk categories) - marrow blast >
10% on differential.
5. Non-Hodgkin's lymphoma in relapse
6. Refractory chronic lymphoid leukemia (CLL) - refractory to fludarabine based regimen,
unrelated donor and haploidentical only
7. The recipient must be <=60 years old at time of registration.
8. The recipient must have a related donor haploidentical for human leukocyte antigen
(HLA), A, B, C, or DR loci. They may be partial matched on the other haplotype.
9. Recovery from prior therapy, chemotherapy, or radiotherapy, as defined by: Eastern
Cooperative Oncology Group (ECOG) performance status equal or less than 2; have
recovered from the toxicity of prior major chemotherapy at the start of the
preparative regimen on this protocol
10. Adequate cardiac and pulmonary function (Left ventricular ejection fraction (LVEF)
>45%, Carbon Monoxide Diffusing Capacity (DL CO)>50% corrected for hemoglobin)
11. Serum creatinine <1.5 mg/dL or creatinine clearance >50 ml/min for those above serum
creatinine of 1.5; serum bilirubin <2.0 mg/dL; Aspartate transaminase (AST)/alanine
aminotransferase (ALT) <2* Upper limits of normal (ULN) (unless secondary to disease)
12. Females of childbearing potential must have a negative serum or urine beta-HCG test
within three weeks of registration. Patients will be informed of the risk of not
receiving adequate contraception.
13. No prior cancer within five years with the exception of surgically cured non-melanoma
skin cancer or in situ cancer of the cervix
14. The recipient and/or the recipient's legal guardian must have been informed of the
investigational nature of this study and have signed a consent form which is in
accordance with Federal guidelines and the guidelines of the participating
15. Donor age must be 4-80 years and weight greater than 20 kg.
16. Medical history and physical examination confirm good health status as defined by
17. Seronegative for HIV Ag, HIV 1+2 Ab, Human T Cell Leukemia Virus (HTLV) I/II Ab,
HbsAg, HbcAb (IgM [combination screening test] and IgG), HCV, RPR for syphilis within
30 days of apheresis collection - If positive for Hepatitis B or C or syphilis, the
recipient must be notified - the recipient may proceed if PI, recipient and donor
agree and there is no substitute donor
18. HLA matching criteria
19. Female donors of child-bearing potential must have a negative serum or urine beta-HCG
test within three weeks of mobilization
20. Capable of undergoing leukapheresis, have adequate venous access, and be willing to
undergo insertion of a central catheter should leukapheresis via peripheral vein be
21. Agreeable to second donation of PBPC (or a bone marrow harvest) should the patient
fail to demonstrate sustained engraftment following the transplant
22. The donor, or legal guardian greater than 18 years of age, must have been informed of
the investigational nature of this study and have signed a consent form in accordance
with Federal Guidelines and the guidelines of the participating institution. If the
donor is less than 18 years of age, parent or legal guardian consent must be
23. The prospective donor will be screened for cytomegalovirus (CMV) seroreactivity and a
seronegative donor will be utilized if available when the patient is seronegative.
1. Participation in other clinical trials which involve investigational drugs or devices
that might influence the endpoints of this study
2. Evidence of active hepatitis (B and/or C) or cirrhosis
3. Neither the recipient nor the donor may be HIV positive
4. Presence of any other active, uncontrolled bacterial, viral or fungal infection.
5. Uncontrolled central nervous system (CNS) involvement with tumor cells
6. Documented allergy to murine proteins or iron dextran
7. The recipient is a lactating female or, if of child-bearing potential, is unwilling
to implement adequate birth control.
8. Severe end-organ dysfunctions, particularly neurologic deficits detectable by
clinical examination or significant intellectual impairment in metabolic disorders
9. Evidence of active infection (including urinary tract infection, or upper respiratory
tract infection) or hepatitis (on screening).
10. Medical or physical reason which makes the donor unlikely to tolerate or cooperate
with growth factor therapy and leukapheresis.
11. Factors that place the donor at increased risk for complications from leukapheresis
or G-CSF therapy such as pulmonary hypertension, coronary artery disease, peripheral
vascular disease, cerebral vascular disease.
12. Lactating female or, if of child-bearing potential, is unwilling to implement
adequate birth control.
13. Donors who are hepatitis positive, Human T-cell lymphotropic virus type I (HTLVI)
positive need consent of Principal Investigator and determination that this is the